Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.504
+0.011 (2.17%)
At close: Jul 19, 2024, 4:00 PM
0.503
-0.001 (-0.14%)
Pre-market: Jul 22, 2024, 6:06 AM EDT
Aligos Therapeutics Revenue
Aligos Therapeutics had revenue of $13.79M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $986.00K. In the year 2023, Aligos Therapeutics had annual revenue of $15.53M with 11.66% growth.
Revenue (ttm)
$13.79M
Revenue Growth
-1.90%
P/S Ratio
2.74
Revenue / Employee
$208,970
Employees
66
Market Cap
37.79M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.53M | 1.62M | 11.66% |
Dec 31, 2022 | 13.91M | 9.55M | 219.04% |
Dec 31, 2021 | 4.36M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Concord Medical Services Holdings | 75.80M |
Precision Optics Corporation | 19.41M |
DarioHealth | 19.04M |
Curis | 9.81M |
Mobile-health Network Solutions | 7.87M |
Cue Biopharma | 7.02M |
ALGS News
- 12 days ago - Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH - GlobeNewsWire
- 2 months ago - Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 3 months ago - Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study - GlobeNewsWire
- 4 months ago - Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies - GlobeNewsWire
- 4 months ago - Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire